A-192621
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526692

CAS#: 195529-54-5

Description: A-192621 is an endothelin-B antagonist. A-192621 markedly enhanced MAP, TPR, and mesenteric, and the renal constrictor effects of ET-1. A-192621 was more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmented constrictor responses to ET-1.


Chemical Structure

img
A-192621
CAS# 195529-54-5

Theoretical Analysis

MedKoo Cat#: 526692
Name: A-192621
CAS#: 195529-54-5
Chemical Formula: C33H38N2O6
Exact Mass: 558.273
Molecular Weight: 558.675
Elemental Analysis: C, 70.95; H, 6.86; N, 5.01; O, 17.18

Price and Availability

Size Price Availability Quantity
5.0mg USD 330.0 2 Weeks
25.0mg USD 890.0 2 Weeks
Bulk inquiry

Synonym: A-192621; A 192621; A192621; A-192621-1; A-192621.1.

IUPAC/Chemical Name: (2R,3R,4S)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-((2,6-diethylphenyl)amino)-2-oxoethyl)-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid

InChi Key: LQEHCKYYIXQEBM-FUKIBTTHSA-N

InChi Code: InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1

SMILES Code: O=C([C@H]1[C@H](C2=CC=C(OCCC)C=C2)N(CC(NC3=C(CC)C=CC=C3CC)=O)C[C@@H]1C4=CC=C(OCO5)C5=C4)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 558.675 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wessale JL, Adler AL, Novosad EI, Calzadilla SV, Dayton BD, Marsh KC, Winn M,
Jae HS, von Geldern TW, Opgenorth TJ, Wu-Wong JR. Pharmacology of endothelin
receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo
studies. Clin Sci (Lond). 2002 Aug;103 Suppl 48:112S-117S. PubMed PMID: 12193067.

2: Wu-Wong JR, Dixon DB, Chiou WJ, Sorensen BK, Liu G, Jae HS, Tasker A, von
Geldern TW, Winn M, Opgenorth TJ. Pharmacology of endothelin receptor antagonists
ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond). 2002
Aug;103 Suppl 48:107S-111S. PubMed PMID: 12193066.

3: Leung SW, Lim SL, Pang CC, Man RY. Use of A-192621 and IRL-2500 to unmask the
mesenteric and renal vasodilator role of endothelin ET(B) receptors. J Cardiovasc
Pharmacol. 2002 Apr;39(4):533-43. PubMed PMID: 11904527.

4: Cullen JP, Bell D, Kelso EJ, McDermott BJ. Use of A-192621 to provide evidence
for involvement of endothelin ET(B)-receptors in endothelin-1-mediated
cardiomyocyte hypertrophy. Eur J Pharmacol. 2001 Apr 13;417(3):157-68. PubMed
PMID: 11334846.

5: Brodsky S, Abassi Z, Wessale J, Ramadan R, Winaver J, Hoffman A. Effects of
A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic
responses to endothelin-1. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S311-3.
PubMed PMID: 11078406.